Home >> Research Area >>Apoptosis>>p53>> HLI 373

HLI 373

Hdm2 ubiquitin ligase (E3) inhibitor CAS# 502137-98-6

HLI 373

Catalog No. BCC2408----Order now to get a substantial discount!

Product Name & Size Price Stock
HLI 373: 5mg $92 In Stock
HLI 373: 10mg Please Inquire In Stock
HLI 373: 20mg Please Inquire Please Inquire
HLI 373: 50mg Please Inquire Please Inquire
HLI 373: 100mg Please Inquire Please Inquire
HLI 373: 200mg Please Inquire Please Inquire
HLI 373: 500mg Please Inquire Please Inquire
HLI 373: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of HLI 373

Number of papers citing our products

Chemical structure

HLI 373

3D structure

Chemical Properties of HLI 373

Cas No. 502137-98-6 SDF Download SDF
PubChem ID 435678 Appearance Powder
Formula C18H23N5O2.2HCl M.Wt 414.33
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in water and to 10 mM in DMSO
Chemical Name 5-[3-(dimethylamino)propylamino]-3,10-dimethylpyrimido[4,5-b]quinoline-2,4-dione
SMILES CN1C2=CC=CC=C2C(=C3C1=NC(=O)N(C3=O)C)NCCCN(C)C
Standard InChIKey LNRUPMPQQGPSQT-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H23N5O2/c1-21(2)11-7-10-19-15-12-8-5-6-9-13(12)22(3)16-14(15)17(24)23(4)18(25)20-16/h5-6,8-9,19H,7,10-11H2,1-4H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of HLI 373

DescriptionInhibitor of Hdm2 ubiquitin ligase (E3). Blocks Hdm2-mediated ubiquitylation and proteasomal degradation of p53; activates p53-dependent transcription. Induces apoptosis in several tumor cell lines that express wild-type p53 such as LOX-IMVI, A549, HT1080 and U2OS.

HLI 373 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

HLI 373 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of HLI 373

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4135 mL 12.0677 mL 24.1354 mL 48.2707 mL 60.3384 mL
5 mM 0.4827 mL 2.4135 mL 4.8271 mL 9.6541 mL 12.0677 mL
10 mM 0.2414 mL 1.2068 mL 2.4135 mL 4.8271 mL 6.0338 mL
50 mM 0.0483 mL 0.2414 mL 0.4827 mL 0.9654 mL 1.2068 mL
100 mM 0.0241 mL 0.1207 mL 0.2414 mL 0.4827 mL 0.6034 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on HLI 373

IC50: N/A

HLI 373 is an inhibitor of Hdm2 ubiquitin ligase (E3).

Hdm2 ubiquitin ligase(E3) is a major regulator of p53 by promoting its ubiquitylation and proteasomal degradation. Therefore, blocking Hdm2-mediated activities may be a therapeutic approach for cancers expressing wild-type p53 [1].

In vitro: HLI373 effectively induces apoptosis of several tumor cells that are sensitive to DNA-damaging agents. HLI373-treated cells showed significantly more DNA retained on the filter, indicating that it does not induce single-strand break in U2OS cells. Having no discernable effect on gp78 or AO7, HLI373 seems prefer to inhibit the ubiquitin ligase activity of Hdm2. Treatment of U2OS cells with HLI373 at 10 Amol/L also leaded to a marked decrease in ubiquitylated species immunoprecipitated with anti-Hdm2, whereas the level of immunoprecipitated Hdm2 increased. Inhibition of Hdm2-mediated ubiquitylation in cells can trigger stabilization of both p53 and Hdm2 and preferential killing of tumor cells expressing wild-type p53. HLI373 increased p53 through inhibiting Hdm2-mediated ubiquitylation and not by inducing a DNA damage response in U2OS cells. HLI373 has high potency in stabilizing Hdm2 and p53. HLI373 inhibits the ubiquitin ligase activity of Hdm2 and induces a wild-type p53-dependent apoptosis in several tumor cells that are sensitive to DNA-damaging agents [1,2].

In vivo: So far, no study in vivo has been conducted.

Clinical trial: So far, no clinical study has been conducted.

References:
[1].  Kitagaki J, Agama KK, Pommier Y, et al. Targeting Tumor Cells Expressing p53 with a Water-soluble Inhibitor of Hdm2. Molecular Cancer Therapeutics, 2008; 7(8): 2445-1454.
[2]. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the Ubiquitin-proteasome System for Cancer Therapy. Cancer Science, 2009, 100(1): 24-28.

Featured Products
New Products
 

References on HLI 373

MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.[Pubmed:28817834]

Br J Cancer. 2017 Oct 10;117(8):1192-1201.

BACKGROUND: Metastasis accounts for the most lethal reason for the death of ovarian cancer patients, but remains largely untreated. Epithelial-mesenchymal transition (EMT) is critical for the conversion of early-stage ovarian tumours into metastatic malignancies. Thus the exploration of the signalling pathways promoting EMT would open potential opportunities for the treatment of metastatic ovarian cancer. Herein, the putative role of MDM2 in regulating EMT and metastasis of ovarian cancer SKOV3 cells was investigated. METHODS: The regulatory effects by MDM2 on cell motility was emulated by wound-healing and transwell assays. The effects on EMT transition and Smad pathway were studied by depicting the expression levels of epithelial marker E-cadherin as well as key components of Smad pathway. To evaluate the clinical relevance of our findings, the correlation of MDM2 expression levels with the stages of 104 ovarian cancer patients was investigated by immunohistochemistry assay. RESULTS: We demonstrate that MDM2 functions as a key factor to drive EMT and motility of ovarian SKOV3 cells, by facilitating the activation of TGF-beta-Smad pathway, which results in the increased transcription of snail/slug and the subsequent loss of E-cadherin levels. Such induction of EMT is sustained in either E3 ligase-depleted MDM2 or E3 ligase inhibitor HLI-373-treated cells, while being impaired by the N-terminal deletion of MDM2, which is also reflected by the inhibitory effects against EMT by Nutlin-3a, the N-terminal targeting agent. The expression levels of MDM2 is highly correlated with the stages of the ovarian cancer patients, and the higher expression of MDM2 together with TGFB are closely correlated with poor prognosis and predict a high risk of ovarian cancer patients. CONCLUSIONS: This study suggests that MDM2 activates Smad pathway to promote EMT in ovarian cancer metastasis, and targeting the N-terminal of MDM2 can reprogram EMT and impede the mobility of cancer cells.

Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.[Pubmed:28577368]

BMC Pharmacol Toxicol. 2017 Jun 2;18(1):40.

BACKGROUND: Protein ubiquitylation is an important post-translational regulation, which has been shown to be necessary for life cycle progression and survival of Plasmodium falciparum. Ubiquitin is a highly conserved 76 amino acid polypeptide, which attaches covalently to target proteins through combined action of three classes of enzymes namely, the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-protein ligase (E3). Ubiquitin E1 and E2 are highly conserved within eukaryotes. However, the P. falciparum E3 ligase is substantially variable and divergent compared to the homologs from other eukaryotes, which make the E3 ligase a parasite-specific target. METHODS: A set of selected E3 ubiquitin ligase inhibitors was tested in vitro against a chloroquine-sensitive P. falciparum D6 strain (PfD6) and a chloroquine-resistant P. falciparum W2 strain (PfW2). The inhibitors were also tested against Vero and transformed THP1 cells for cytotoxicity. The lead antimalarial E3 ubiquitin ligase inhibitors were further evaluated for the stage-specific antimalarial action and effects on cellular development of P. falciparum in vitro. Statistics analysis was done by two-way ANOVA followed by Tukey and Sidak multiple comparison test using GraphPad Prism 6. RESULTS: E3 ligase inhibitors namely, JNJ 26854165, HLI 373 and Nutlin 3 showed prominent antimalarial activity against PfD6 and PfW2. These inhibitors were considerably less cytotoxic to mammalian Vero cells. JNJ 26854165, HLI 373 and Nutlin 3 blocked the development of P. falciparum parasite at the trophozoite and schizont stages, resulting in accumulation of distorted trophozoites and immature schizonts. CONCLUSIONS: Interruption of trophozoites and schizont maturation by the antimalarial E3 ligase inhibitors suggest the role of ubiquitin/proteasome functions in the intraerythrocytic development of malaria parasite. The ubiquitin/proteasome functions may be critical for schizont maturation. Further investigations on the lead E3 ligase inhibitors shall provide better understanding regarding the importance of E3 ligase functions in the malaria parasite as a potential new antimalarial drug target and a new class of antimalarial drug leads.

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.[Pubmed:18723490]

Mol Cancer Ther. 2008 Aug;7(8):2445-54.

The tumor suppressor protein p53 is a potent inducer of apoptosis in transformed cells. Hdm2 is an ubiquitin ligase (E3) that acts as a major regulator of p53 by promoting its ubiquitylation and proteasomal degradation. For this reason, inhibiting the E3 activity of Hdm2 has been proposed as a therapeutic approach for cancers expressing wild-type p53. We previously identified a family of small molecules (HLI98s, 7-nitro-10-aryl-5-deazaflavins) that inhibit the E3 activity of Hdm2, increase cellular p53, and selectively kill transformed cells expressing wild-type p53. However, issues of both potency and solubility in aqueous solution limit the utility of the HLI98s. Here, we report that a highly soluble derivative of the HLI98s, which has a 5-dimethylaminopropylamino side chain but lacks the 10-aryl group (HLI373), has greater potency than the HLI98s in stabilizing Hdm2 and p53, activating p53-dependent transcription, and inducing cell death. Furthermore, we show that HLI373 is effective in inducing apoptosis of several tumor cells lines that are sensitive to DNA-damaging agents. These results suggest that HLI373 could serve as a potential lead for developing cancer therapeutics based on inhibition of the ubiquitin ligase activity of Hdm2.

Targeting the ubiquitin-proteasome system for cancer therapy.[Pubmed:19037995]

Cancer Sci. 2009 Jan;100(1):24-8.

The ubiquitin-proteasome system plays a critical role in controlling the level, activity and location of various cellular proteins. Significant progress has been made in investigating the molecular mechanisms of ubiquitination, particularly in understanding the structure of the ubiquitination machinery and identifying ubiquitin protein ligases, the primary specificity-determining enzymes. Therefore, it is now possible to target specific molecules involved in ubiquitination and proteasomal degradation to regulate many cellular processes such as signal transduction, proliferation and apoptosis. In particular, alterations in ubiquitination are observed in most, if not all, cancer cells. This is manifested by destabilization of tumor suppressors, such as p53, and overexpression of oncogenes such as c-Myc and c-Jun. In addition to the development and clinical validation of proteasome inhibitor, bortezomib, in myeloma therapy, recent studies have demonstrated that it is possible to develop inhibitors for specific ubiquitination and deubiquitination enzymes. With the help of structural studies, rational design and chemical synthesis, it is conceivable that we will be able to use 'druggable' inhibitors of the ubiquitin system to evaluate their effects in animal tumor models in the not-so-distant future.

Description

Hdm2 inhibitor; activates p53-dependent transcription

Keywords:

HLI 373,502137-98-6,Natural Products,p53, buy HLI 373 , HLI 373 supplier , purchase HLI 373 , HLI 373 cost , HLI 373 manufacturer , order HLI 373 , high purity HLI 373

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: